Siemens submits digital mammography application

Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

As recommendations have become a commonplace expectation on radiology reports, is there a point where we are crossing the line?

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

In a 10-year study involving over 5,400 women with nearly 85 percent having dense breasts, contrast-enhanced mammography (CEM) demonstrated a 95.9 percent sensitivity rate for breast cancer.

For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.